Opaleye Group reports 1.256M shares in Q32 Bio (NASDAQ: QTTB)

Rhea-AI Filing Summary

Q32 Bio Inc. ownership filing: Opaleye Management Inc., together with Opaleye, L.P. and James Silverman, reports beneficial ownership of 1,256,228 shares of Common Stock, representing 8.65% of the class.

The filing states the share count is based on 14,524,726 Common Shares outstanding as of 02/17/2026, cited from Q32 Bio Inc.'s 424B5 Prospectus.

Insights

Corporate Governance Specialist

Opaleye reports an 8.65% shared beneficial stake in Q32 Bio.

Opaleye, the adviser and the Fund are reported as having shared voting and shared dispositive power over 1,256,228 shares. The filing attributes ownership to the Fund with the Adviser and Mr. Silverman linked by control.

Ownership is measured against 02/17/2026 outstanding shares from a 424B5 Prospectus. Future trading or additional filings would change disclosure; timing and cash‑flow treatment are not stated in the provided excerpt.

Regulatory Compliance Analyst

The statement is a routine Section 13 disclosure, not an admission of personal beneficial ownership.

The filing clarifies it is submitted by three reporting persons and contains a joint filing agreement. It notes the Adviser serves the Fund and Mr. Silverman controls the Adviser but disclaims automatic beneficial‑owner status.

Record labels and CUSIP 746964105 are provided; subsequent Schedule 13D/13G or Form 4 filings would reflect any material changes to position or voting intent.

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13G

UNDER THE SECURITIES EXCHANGE ACT OF 1934

Q32 Bio Inc.

(Name of Issuer)

Common Stock, par value $0.0001 per share

(Title of Class of Securities)

746964105

(CUSIP Number)

02/19/2026

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

Rule 13d-1(b)

Rule 13d-1(c)

Rule 13d-1(d)

SCHEDULE 13G

CUSIP No. 746964105

1

Names of Reporting Persons

Opaleye Management Inc.

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

MASSACHUSETTS

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 0.00
6	Shared Voting Power 1,256,228.00
7	Sole Dispositive Power 0.00
8	Shared Dispositive Power 1,256,228.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

1,256,228.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

8.65 %

12

Type of Reporting Person (See Instructions)

IA, CO

SCHEDULE 13G

CUSIP No. 746964105

1

Names of Reporting Persons

Opaleye, L.P.

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

MASSACHUSETTS

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 0.00
6	Shared Voting Power 1,256,228.00
7	Sole Dispositive Power 0.00
8	Shared Dispositive Power 1,256,228.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

1,256,228.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

8.65 %

12

Type of Reporting Person (See Instructions)

PN

Comment for Type of Reporting Person: Based on 14,524,726 Common Shares outstanding as of 02/17/2026 as reported by Q32 Bio Inc. on 02/17/2026, in its 424B5 Prospectus.

SCHEDULE 13G

CUSIP No. 746964105

1

Names of Reporting Persons

James Silverman

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

UNITED STATES

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 0.00
6	Shared Voting Power 1,256,228.00
7	Sole Dispositive Power 0.00
8	Shared Dispositive Power 1,256,228.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

1,256,228.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

8.65 %

12

Type of Reporting Person (See Instructions)

IN

SCHEDULE 13G

Item 1.
(a)	Name of issuer: Q32 Bio Inc.
(b)	Address of issuer's principal executive offices: 830 Winter Street, Waltham, MA 02451
Item 2.
(a)	Name of person filing: Opaleye Management Inc. Opaleye, L.P. James Silverman This statement is filed by (i) Opaleye Management Inc. (the "Adviser"), (ii) Opaleye, L.P. (the "Fund") and (iii) James Silverman with respect to the shares of common stock, par value $0.0001 per share ("Common Stock"), of Q32 Bio Inc. (the "Issuer") directly held by the Fund. The Adviser serves as investment adviser to the Fund. Mr. Silverman exercises control over the Adviser. The filing of this statement should not be construed as an admission that any of the foregoing persons is, for the purposes of Section 13 of the Securities Exchange Act, the beneficial owner of the shares reported herein.
(b)	Address or principal business office or, if none, residence: One Boston Place, 26th Floor, Boston, MA 02108
(c)	Citizenship: Opaleye Management Inc. - Massachusetts Opaleye, L.P. - Massachusetts James Silverman - United States
(d)	Title of class of securities: Common Stock, par value $0.0001 per share
(e)	CUSIP No.: 746964105
Item 3.	If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
(a)	Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
(b)	Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
(c)	Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
(d)	Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
(e)	An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
(f)	An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
(g)	A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
(h)	A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
(i)	A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
(j)	A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J), please specify the type of institution:
(k)	Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
Item 4.	Ownership
(a)	Amount beneficially owned: 1,256,228.00
(b)	Percent of class: 8.65 %
(c)	Number of shares as to which the person has:
	(i) Sole power to vote or to direct the vote: 0
	(ii) Shared power to vote or to direct the vote: 1,256,228.00
	(iii) Sole power to dispose or to direct the disposition of: 0
	(iv) Shared power to dispose or to direct the disposition of: 1,256,228.00
Item 5.	Ownership of 5 Percent or Less of a Class.
	Not Applicable
Item 6.	Ownership of more than 5 Percent on Behalf of Another Person.
	Not Applicable
Item 7.	Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
	Not Applicable
Item 8.	Identification and Classification of Members of the Group.
	Not Applicable
Item 9.	Notice of Dissolution of Group.
	Not Applicable

Item 10.

Certifications:

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11.

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Opaleye Management Inc.

Signature:	/s/ James Silverman
Name/Title:	President
Date:	02/20/2026

Opaleye, L.P.

Signature:	/s/ James Silverman
Name/Title:	General Partner
Date:	02/20/2026

James Silverman

Signature:	/s/ James Silverman
Name/Title:	Individually
Date:	02/20/2026

Exhibit Information

Exhibit 99.1 Joint Filing Agreement by and among the reporting persons

FAQ

What stake does Opaleye report in Q32 Bio (QTTB)?

Opaleye reports beneficial ownership of 1,256,228 shares, equal to 8.65% of Q32 Bio's common stock. This percentage uses 14,524,726 shares outstanding as of 02/17/2026, per the cited 424B5 prospectus.

Who are the reporting persons on the Schedule 13G for Q32 Bio?

The Schedule 13G is filed jointly by Opaleye Management Inc., Opaleye, L.P., and James Silverman. The Adviser manages the Fund and Mr. Silverman is reported to exercise control over the Adviser.

Does the filing state how many shares were outstanding for the percentage calculation?

Yes. The filing cites 14,524,726 Common Shares outstanding as of 02/17/2026, taken from Q32 Bio's 424B5 Prospectus, which is the basis for the reported 8.65% ownership figure.

What voting and dispositive powers are reported by Opaleye?

The filing reports 0 shares with sole voting or dispositive power and 1,256,228 shares with shared voting power and shared dispositive power, reflecting the Fund's reported control structure over those shares.

Does the Schedule 13G assert that James Silverman personally owns the shares?

No. The filing states the shares are directly held by the Fund and the filing should not be construed as an admission that any reporting person, including James Silverman, is the beneficial owner for Section 13 purposes.